HomeCompareCHGCF vs PM

CHGCF vs PM: Dividend Comparison 2026

CHGCF yields 2.90% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHGCF wins by $350.22M in total portfolio value· pulled ahead in Year 3
10 years
CHGCF
CHGCF
● Live price
2.90%
Share price
$55.78
Annual div
$1.62
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.27M
Annual income
$328,490,171.71
Full CHGCF calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — CHGCF vs PM

📍 CHGCF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHGCFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHGCF + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHGCF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHGCF
Annual income on $10K today (after 15% tax)
$246.26/yr
After 10yr DRIP, annual income (after tax)
$279,216,645.95/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, CHGCF beats the other by $279,214,518.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHGCF + PM for your $10,000?

CHGCF: 50%PM: 50%
100% PM50/50100% CHGCF
Portfolio after 10yr
$175.16M
Annual income
$164,246,337.16/yr
Blended yield
93.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

CHGCF
No analyst data
Altman Z
21.8
Piotroski
5/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHGCF buys
0
PM buys
0
No recent congressional trades found for CHGCF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHGCFPM
Forward yield2.90%3.49%
Annual dividend / share$1.62$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%17.2%
Portfolio after 10y$350.27M$49.6K
Annual income after 10y$328,490,171.71$2,502.61
Total dividends collected$348.65M$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CHGCF vs PM ($10,000, DRIP)

YearCHGCF PortfolioCHGCF Income/yrPM PortfolioPM Income/yrGap
1$11,279$579.45$11,650$409.56$371.00PM
2$13,291$1,221.65$13,592$497.49$301.00PM
3← crossover$16,912$2,690.62$15,882$605.21+$1.0KCHGCF
4$24,495$6,399.38$18,589$737.41+$5.9KCHGCF
5$43,534$17,324.98$21,794$899.94+$21.7KCHGCF
6$104,136$57,554.30$25,597$1,100.16+$78.5KCHGCF
7$368,757$257,331.25$30,118$1,347.30+$338.6KCHGCF
8$2,097,816$1,703,246.11$35,505$1,652.97+$2.06MCHGCF
9$20,356,014$18,111,350.35$41,940$2,031.88+$20.31MCHGCF
10$350,271,106$328,490,171.71$49,643$2,502.61+$350.22MCHGCF

CHGCF vs PM: Complete Analysis 2026

CHGCFStock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Full CHGCF Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this CHGCF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHGCF vs SCHDCHGCF vs JEPICHGCF vs OCHGCF vs KOCHGCF vs MAINCHGCF vs MOCHGCF vs BTICHGCF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.